Antimicrobial resistance in bacterial pathogens causing community-acquired and hospital-acquired lower respiratory tract infections (2010–24): a systematic review and meta-analysis
The Lancet Microbe · 2026
DOI: 10.1016/j.lanmic.2026.101361 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Lancet Microbe, 2026. Verfasst von Gilbert Lazarus und 15 weiteren Autor:innen. Beteiligte Einrichtung: Oxford University Clinical Research Unit Indonesia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia. Hauptthemen laut MEDLINE: Community-Acquired Infections, Anti-Bacterial Agents, Cross Infection, Drug Resistance, Bacterial. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JG CDC HHS, Wellcome Trust, World Health Organization.
Abstract (Originalsprache)
BACKGROUND: Data on the prevalence of antimicrobial resistance (AMR) among the main bacterial pathogens causing community-acquired lower respiratory tract infections (CA-LRTIs) and hospital-acquired lower respiratory tract infections (HA-LRTIs) are scarce. This review estimated LRTI-specific AMR prevalence and time trends globally and for each WHO region. METHODS: In this systematic review and meta-analysis, we systematically searched Embase, Global Health, and MEDLINE for original peer-reviewed articles, published between Jan 1, 2010, and May 16, 2024, describing microbiologically confirmed LRTI caused by WHO's Global Antimicrobial Resistance and Use Surveillance System (GLASS) target bacteria, alongside antimicrobial susceptibility testing results. We included studies describing individuals seeking care at a health-care facility with a microbiologically confirmed LRTI, a culture-confirmed GLASS target bacterial pathogen from a lower respiratory tract or expectorated sputum specimen, and antimicrobial susceptibility testing results for one GLASS pathogen-antimicrobial combination or more, for 20 isolates or more. We excluded non-original or non-peer-reviewed articles. We used multilevel random-effect meta-analysis to estimate AMR prevalence for relevant pathogen-antimicrobial combinations. To assess article quality, we adopted the Microbiology Investigation Criteria for Reporting Objectively (MICRO) checklist. This review was registered with PROSPERO (CRD42024549753). FINDINGS: From 10 208 reports identified after deduplication, we included 506 reports and extracted data on 336 389 respiratory isolates from 51 countries. For CA-LRTIs, regional variations were observed in the prevalence of penicillin resistance in Streptococcus pneumoniae (32·4% globally [range: 26·5-38·7]; n=6475 isolates); ampicillin resistance in Haemophilus influenzae (51·6% [27·0-73·4]; n=4305); third-generation cephalosporin resistance (38·8% [21·3-84·0]; n=4198) and carbapenem resistance (7·2% [1·2-29·0]; n=3437) in Klebsiella pneumoniae; and meticillin resistance in Staphylococcus aureus (MRSA; 33·2% [11·0-43·2]; n=4698). For HA-LRTIs, regional prevalence of carbapenem resistance varied for Acinetobacter spp (86·0% [78·7-93·4]; n=17 843), Pseudomonas aeruginosa (42·1% [32·3-48·6]; n=22 341), K pneumoniae (37·0% [6·9-52·3]; n=8310), and Escherichia coli (13·2% [0·41-45·2]; n=6229); and for MRSA (55·2% [22·3-79·0]; n=6060). For HA-LRTIs, prevalence of third-generation cephalosporin resistance and carbapenem resistance in E coli was higher in low-income and middle-income countries (73·2% [65·5-80·3] vs 18·3% [5·2-37·0], p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Oxford University Clinical Research Unit Indonesia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
- Faculty of Veterinary Medicine, University of Calgary, Calgary, AB, Canada; AMR - One Health Consortium, Calgary, AB, Canada; Pan American Health Organization (PAHO)/WHO Collaborating Centre for Research on Antimicrobia…
- Department of Antimicrobial Resistance, WHO, Geneva, Switzerland.
- AMR - One Health Consortium, Calgary, AB, Canada; Pan American Health Organization (PAHO)/WHO Collaborating Centre for Research on Antimicrobial Resistance and Appropriate Use of Antimicrobials, University of Calgary, C…
- Department of Antimicrobial Resistance, WHO, Geneva, Switzerland; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Epidemiology of Infectious Diseases, J…
- WHO Library and Digital Information Networks, Science Division, WHO, Geneva, Switzerland.
Förderung
- JG CDC HHS
- Wellcome Trust
- World Health Organization
- Centers for Disease Control and Prevention
Zitieren
APA
Lazarus, G., Caddey, B., Dean, A., Wangsaputra, V. K., Febrina, F., Radiani, S. P., Xiong, Y., Conly, J. M., Barkema, H. W., van Kleef, E., Tosas Auguet, O., Kothari, K. U., Bertagnolio, S., Nobrega, D. B., Hamers, R. L., & WHO AMR Prevalence Systematic Review Collaborators (2026). Antimicrobial resistance in bacterial pathogens causing community-acquired and hospital-acquired lower respiratory tract infections (2010–24): a systematic review and meta-analysis. The Lancet Microbe. https://doi.org/10.1016/j.lanmic.2026.101361
Vancouver
Lazarus G, Caddey B, Dean A, Wangsaputra VK, Febrina F, Radiani SP, et al. Antimicrobial resistance in bacterial pathogens causing community-acquired and hospital-acquired lower respiratory tract infections (2010–24): a systematic review and meta-analysis. The Lancet Microbe. 2026. doi:10.1016/j.lanmic.2026.101361
BibTeX
@article{Lazarus2026,
author = {Lazarus, Gilbert and Caddey, Benjamin and Dean, Anna and Wangsaputra, Vincent Kharisma and Febrina, Florentina and Radiani, Shafira Permata and Xiong, Yindi and Conly, John M and Barkema, Herman W and van Kleef, Esther and Tosas Auguet, Olga and Kothari, Kavita U and Bertagnolio, Silvia and Nobrega, Diego B and Hamers, Raph L and WHO AMR Prevalence Systematic Review Collaborators, WHO AMR Prevalence Systematic Review Collaborators},
title = {Antimicrobial resistance in bacterial pathogens causing community-acquired and hospital-acquired lower respiratory tract infections (2010–24): a systematic review and meta-analysis},
journal = {The Lancet Microbe},
year = {2026},
doi = {10.1016/j.lanmic.2026.101361}
}
EUVIMED